Sunday 18 October 2026 Export PRLD’s income statement to Excel — free account

Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.1 million, up 73.4% from fiscal 2024. In the quarter to June 2026, revenue grew 42.6%, EPS grew 65.9% and free cash flow grew 40.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.26 0.06 −1.81%

Follow PRLD

Alert me

Market cap: $265.0M
P/E: 0.0×
Fwd P/E: −16.6×
Dividend yield: —
F-score: n/a
Altman Z: −6.83
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 25.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	2	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 54.54%

Capital & Financial Ratios $m

Market Cap 264.95

Revenue 22.42

Net Income (60.49)

Free Cash Flow (33.25)

Net Debt (151.76)

Current Ratio 4.07

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (16.60)

P/S ratio 14.30

P/B ratio 2.40

Past 5Y EPS Growth —

This Y EPS Growth 68.84%

Next Y EPS Growth (18.41%)

Next Y revenue growth 220.51%

Next 5Y EPS Growth 57.36%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 72.35%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	233	134	103	152
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	236	136	106	155

	2023	2024	2025	Q'26
Payables	5	8	4	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	22	26	53	38

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(20.21%)	(29.45%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	5	6	—	—	—
’25	—	—	7	6	12

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(22)	(16)	—	—	—
’25	(34)	(26)	(19)	23	(56)
’24	(32)	(23)	(27)	(21)	(103)
’23	(30)	(28)	(26)	(24)	(107)
’22	(22)	(18)	(20)	(23)	(84)
’21	(16)	(20)	(22)	(26)	(84)
’20	(10)	(9)	(13)	(15)	(46)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(22)	(16)	—	—	—
’25	(34)	(26)	(19)	23	(56)
’24	(32)	(23)	(27)	(21)	(104)
’23	(31)	(29)	(26)	(25)	(111)
’22	(23)	(19)	(21)	(23)	(87)
’21	(17)	(20)	(22)	(26)	(86)
’20	(10)	(9)	(13)	(15)	(47)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.13)	(0.14)	—	—	—
’25	(0.42)	(0.41)	(0.26)	(0.20)	(1.29)
’24	(0.42)	(0.46)	(0.43)	(0.38)	(1.68)
’23	(0.58)	(0.54)	(0.45)	(0.47)	(2.02)
’22	(0.63)	(0.58)	(0.63)	(0.60)	(2.44)
’21	(0.47)	(0.58)	(0.66)	(0.71)	(2.43)
’20	(5.12)	(5.50)	(5.25)	(0.45)	(4.56)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	23.69	10.96	3.87	1.66	0.80	0.61	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	89.06	95.38	13.40	8.57	6.80	4.22
People
People	Employees	—	—	—	51	68	116	122	128	131	79
	Revenue/emp, $m	—	—	—	0.00	0.00	0.00	0.00	0.00	0.05	0.15
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	7	12
	Gross margin, %	—	—	0.00	0.00	0.00	0.00	0.00	—	100.00	100.00
	EBT	—	—	(15)	(28)	(57)	(112)	(115)	(122)	(127)	(99)
	EBT margin, %	—	—	0.00	0.00	0.00	0.00	0.00	0.00	(1,816.76)	(819.59)
	Net income	—	0	(15)	(28)	(57)	(112)	(115)	(122)	(127)	(99)
	Depreciation	—	—	0	0	1	2	4	(2)	(3)	1
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.09	0.16
	Earnings	—	—	(0.34)	(16.52)	(4.56)	(2.43)	(2.44)	(2.02)	(1.68)	(1.29)
	Cash flow	—	—	(0.30)	(15.38)	(3.70)	(1.81)	(1.77)	(1.77)	(1.36)	(0.73)
	Capex	—	—	0.00	(0.47)	(0.05)	(0.05)	(0.06)	(0.06)	(0.01)	0.00
	Free cash flow	—	—	(0.30)	(15.84)	(3.75)	(1.86)	(1.83)	(1.83)	(1.37)	(0.73)
	Book value	—	—	0.32	10.20	17.00	6.21	4.13	3.93	1.73	0.89
	Shares, m	—	—	44	2	12	46	47	60	76	77
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	0.00	0.00
	P/S	—	—	—	—	—	—	—	—	0.00	11.66
	P/B	—	—	—	—	—	—	—	—	0.74	3.25
	EV/Sales	—	—	—	—	—	—	—	—	0.00	6.27
	EV/FCF	—	—	—	—	—	—	—	—	0.35	(2.13)
Cash, $m
Cash, $m	Operating cash flow	—	—	(13)	(26)	(46)	(84)	(84)	(107)	(103)	(56)
	Capex	—	—	(1)	(1)	(1)	(2)	(3)	(4)	(1)	0
	Free cash flow	—	—	(13)	(26)	(47)	(86)	(87)	(111)	(104)	(56)
Balance, $m
Balance, $m	Working capital	—	—	13	15	209	276	183	214	110	53
	Total debt	—	—	—	0	—	2	2	—	—	—
	Net debt	—	—	(16)	(19)	(218)	(291)	(202)	(233)	(134)	(103)
	Shareholders’ equity	—	—	14	17	212	286	195	237	131	69
Returns, %
Returns, %	ROA	—	—	(178.96)	(144.06)	(46.39)	(42.25)	(43.93)	(48.91)	(56.12)	(62.81)
	ROIC	—	—	0.00	0.00	0.00	0.00	0.00	(1,989.73)	0.00	0.00
	ROE	—	—	40.72	76.47	(69.95)	(44.85)	(47.97)	(56.33)	(69.01)	(99.45)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IPSC Century Therapeutics, Inc.	$271.6M	— (loss-making)	— (loss-making)	+12,667.72% (above 0%: growing)	n/m	+26.66% (above 0%: growing)	100.00%	0.00%	Compare
EYPT EyePoint, Inc.	$270.7M	— (loss-making)	— (loss-making)	−90.49% (below 0%: shrinking)	n/m	+0.41% (above 0%: growing)	100.00%	(19,207.10%)	Compare
PALI Palisade Bio, Inc.	$268.4M	2.2×	— (loss-making)	+19,900.00% (above 0%: growing)	n/m	−318.44% (below 0%: shrinking)	100.00%	(2,339.60%)	Compare
ABEO Abeona Therapeutics Inc.	$265.9M	— (loss-making)	— (loss-making)	+225.14% (above 0%: growing)	n/m	+17.11% (above 0%: growing)	63.30%	(119.97%)	Compare
PRLD Prelude Therapeutics Incorporated	$265.0M	— (loss-making)	— (loss-making)	+42.60% (above 0%: growing)	n/m	+40.32% (above 0%: growing)	100.00%	(270.93%)
CABA Cabaletta Bio, Inc.	$262.8M	— (loss-making)	—	—	n/m	−35.72% (below 0%: shrinking)	0.00%	0.00%	Compare
XFOR X4 Pharmaceuticals, Inc.	$261.8M	— (loss-making)	— (loss-making)	+346.33% (above 0%: growing)	n/m	+13.76% (above 0%: growing)	81.64%	(186.13%)	Compare
RCKT Rocket Pharmaceuticals, Inc.	$259.1M	— (loss-making)	—	—	n/m	+19.16% (above 0%: growing)	0.00%	0.00%	Compare
VNDA Vanda Pharmaceuticals Inc.	$256.4M	— (loss-making)	— (loss-making)	−3.92% (below 0%: shrinking)	n/m	−101.02% (below 0%: shrinking)	92.95%	(126.28%)	Compare
Median of peers	$264.3M	—	—	+285.74%	—	+7.09%	87.30%	(123.12%)

All 614 Biotechnology stocks →

Prelude Therapeutics Incorporated (PRLD) key facts

Strength: Prelude Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.1 million, up 73.4% from fiscal 2024.
Prelude Therapeutics Incorporated (PRLD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PRLD traded at $3.26, a market capitalization of $265.0 million.
Return on equity was −99.5% and debt-to-equity 0.00.
Its Altman Z-score is −6.83 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.